Effect of grapefruit juice on the bioactivation of prasugrel

British Journal of Clinical Pharmacology

Volumn 80, Issue 1, 2015, Pages 139-145

  Holmberg, Mikko T ^a   Tornio, Aleksi ^a   Hyvärinen, Hanna ^a   Neuvonen, Mikko ^a   Neuvonen, Pertti J ^a   Backman, Janne T ^a   Niemi, Mikko ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

cytochrome P450 3A4; drug interaction; grapefruit juice; prasugrel

Indexed keywords

5 [2 CYCLOPROPYL 1 (2 FLUOROPHENYL) 2 OXOETHYL] 4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 2(3H) ONE; DRUG METABOLITE; PRASUGREL; R 138727; UNCLASSIFIED DRUG; WATER; ANTITHROMBOCYTIC AGENT; PRODRUG;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BIOACTIVATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; FEMALE; GRAPEFRUIT JUICE; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC ACTIVATION; NORMAL HUMAN; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PLATELET AGGREGATION ASSAY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION ANALYZER; YOUNG ADULT; ADVERSE EFFECTS; BEVERAGE; BLOOD; CROSSOVER PROCEDURE; DRUG EFFECTS; FOOD DRUG INTERACTION; GRAPEFRUIT; METABOLISM; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE;

ACTIVATION, METABOLIC; BEVERAGES; BLOOD PLATELETS; CITRUS PARADISI; CROSS-OVER STUDIES; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PRODRUGS; YOUNG ADULT;

EID: 84933050799     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12581     Document Type: Article

References (28)

1. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM,. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
2. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L,. French Registry of Acute ST-Elevation and Non-ST- Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75.
3. Weerakkody GJ, Jakubowski JA, Brandt JT, Payne CD, Naganuma H, Winters KJ,. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. J Cardiovasc Pharmacol Ther 2007; 12: 205-12.
4. Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, Stavrou EF, Hahalis G, Athanassiadou A,. Prasugrel overcomes high on-clopidogrel platelet reactivity post- stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19∗2 genotyping. JACC Cardiovasc Interv 2011; 4: 403-10.
5. i-linked P2T antagonist, CS-747. Br J Pharmacol 2001; 132: 47-54.
6. Asai F, Jakubowski JA, Naganuma H, Brandt JT, Matsushima N, Hirota T, Freestone S, Winters KJ,. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Platelets 2006; 17: 209-17.
7. Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ,. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006; 34: 600-7.
8. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS,. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553-60.
9. Farid NA, Payne CD, Small DS, Winters KJ, Ernest II CS, Brandt JT, Darstein C, Jakubowski JA, Salazar DE,. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81: 735-41.
10. Ancrenaz V, Deglon J, Samer C, Staub C, Dayer P, Daali Y, Desmeules J,. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin Pharmacol Toxicol 2013; 112: 132-7.
11. Farid NA, Jakubowski JA, Payne CD, Li YG, Jin Y, Ernest II CS, Winters KJ, Brandt JT, Salazar DE, Small DS,. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Curr Med Res Opin 2009; 25: 1821-9.
12. Bailey DG, Spence JD, Munoz C, Arnold JM,. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-9.
13. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB,. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2545-53.
14. Bailey DG, Dresser GK, Kreeft JH, Munoz C, Freeman DJ, Bend JR,. Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ther 2000; 68: 468-77.
15. Bailey DG, Dresser G, Arnold JMO,. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? Can Med Assoc J 2013; 185: 309-16.
16. Holmberg MT, Tornio A, Joutsi-Korhonen L, Neuvonen M, Neuvonen PJ, Lassila R, Niemi M, Backman JT,. Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. Br J Clin Pharmacol 2013; 75: 1488-96.
17. Holmberg M, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M,. Grapefruit juice inhibits the metabolic activation of clopidogrel. Clin Pharmacol Ther 2014; 95: 307-13.
18. Farid NA, McIntosh M, Garofolo F, Wong E, Shwajch A, Kennedy M, Young M, Sarkar P, Kawabata K, Takahashi M, Pang H,. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007; 21: 169-79.
19. 12 inhibition with the point-of- care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 2009; 157: 562.e1-e9.
20. Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ,. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 2011; 7: 267-86.
21. Lilja JJ, Kivistö KT, Backman JT, Lamberg TS, Neuvonen PJ,. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 1998; 64: 655-60.
22. Lilja JJ, Kivistö KT, Backman JT, Neuvonen PJ,. Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol 2000; 56: 411-5.
23. Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequiqnot E, Waldman SA, Greenberg HE,. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 2003; 43: 831-9.
24. Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y,. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 2000; 378: 356-63.
25. Läpple F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H, Griese EU, Eichelbaum M, Kivistö KT,. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 2003; 13: 565-75.
26. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, Yang D, Shi D, Yan B,. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 2006; 319: 1467-76.
27. Farid NA, Kurihara A, Wrighton SA,. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010; 50: 126-42.
28. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A,. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-9.